Greater Asia News
Menarini Asia-Pacific Enters into an Exclusive Licensing Agreement with Astellas to Commercialize Smyraf® in Taiwan and select South-East Asian markets
Menarini Asia-Pacific has entered into a long-term exclusive licensing partnership with Astellas Pharma Inc. (Astellas) for the development, manufacturing and commercialization of the orally administered Janus kinase (JAK) inhibitor Smyraf® 50 mg and 100 mg Tablets (generic name: peficitinib hydrobromide) in Taiwan for the treatment of rheumatoid arthritis. Smyraf® has been approved in Taiwan and has patent protection for composition of matter until 2032.
AWAK TECHNOLOGIES RAISES US$20+ MILLION, READYING ITS WEARABLE DIALYSIS DEVICE FOR US-BASED PIVOTAL TRIAL
AWAK Technologies (AWAK), a pioneering medical technology company focused on dialysis using regeneration technology for end-stage renal disease, today announced it has successfully raised US$20+ million in Series B funding.
ACM Biolabs Announces Positive Topline Results from a Phase I Trial of SARS-CoV-2 Booster Vaccine ACM-001
ACM Biolabs, a biotechnology company using its next-generation polymer-based delivery platform to develop new nano formulations for use in multiple therapeutic fields, today announced positive topline results from a Phase I trial of ACM-001, the Company's first clinical-stage development program.
alveoair® has received U.S. FDA clearance, marking a significant advancement in respiratory care
alveofit® (Roundworks Technologies Private Limited) is thrilled to announce that its groundbreaking product, alveoair® spirometer, has earned U.S. FDA clearance for distribution in the United States. Specializing in digital therapeutics for respiratory care, the company is committed to delivering affordable and interoperable lung health solutions.
Viatris Announces U.S. FDA Tentative Approval of a Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), a Once-daily Treatment for Children Living with HIV
Tentative approval will help enhance access to WHO-recommended paediatric regimen with the goal of improved adherence of HIV treatment for children in low- and middle-income countries
Celltrion Group to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
Celltrion Group today announced that the company will be attending the Morgan Stanley 21st Annual Global Healthcare Conference in New York City on Monday, September 11, 2023. Jungjin Seo, Chairman, will be speaking in a fireside chat at 3:35 p.m. ET.
Seegene Unveils ‘Open Innovation Program Powered by Seegene’ in Partnership with Springer Nature
Seegene Inc. (KQ096530), a leading South Korean company providing a total solution for PCR molecular diagnostics, unveiled today its 'Open Innovation Program powered by Seegene (Open Innovation Program)' in partnership with Springer Nature, a world-leading provider of services to the research community. The inaugural program is available globally and is the first step in empowering experts, scientists, and clinicians to develop syndromic quantitative PCR (qPCR) assays across all fields.
Alteogen’s Tergase® (Novel Recombinant Human Hyaluronidase Injection) Shows Excellent Immunogenicity Profile
Alteogen expects Tergase® will replace commercially available animal-derived hyaluronidase products and their significant disadvantages.
Mitsubishi Electric, Okayama University, and Osaka University Develop Magnetic Particle Imaging Device Capable of Producing Images of Human Brain
Mitsubishi Electric Corporation (TOKYO: 6503), Okayama University and Osaka University’s Graduate School of Engineering announced today that they have developed a magnetic particle imaging device capable of sensitive imaging of magnetic particles in an area equivalent in size to that of the human brain, in a project supported by the Japan Agency for Medical Research and Development (AMED).
Otsuka collaborates with ShapeTX to develop novel AAV gene therapies for ocular diseases
Otsuka Pharmaceutical Co., Ltd. (Otsuka) and ShapeTX, the programmable medicine company using AI and RNA to end genetic diseases, today announce a multi-target collaboration to develop intravitreally-delivered adeno-associated viruses (AAVs) for ocular diseases.
